Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2026-06-23 21:32:23 ET · period of report 2026-06-22 · accession 0001636282-26-000084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-23 21:32 | 2026-06-22 | SYRE | HENDERSON MICHAEL THOMAS | Dir | S - Sale | $100.00 | -20.0K | 68.6K | -23% | -$2.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-22 | S | D | 20,000 | $100.00 | 68,606 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. |